Identity
FOXO4-DRI is an experimental peptide designed to disrupt FOXO4–p53 interaction in senescent cells.
Selected study only; not a complete clinical review.
Peptide library
FOXO4-DRI
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
Senescent-cell targeting and mouse functional outcomes are preclinical findings. Healthy-human rejuvenation, selective effects in human tissues and long-term toxicity remain unestablished.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Cell experiments and mouse models of aging and chemotherapy injury.
What the sources found
The peptide promoted senescent-cell apoptosis and improved selected mouse outcomes; human rejuvenation was not demonstrated.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
FOXO4-DRI is an experimental peptide designed to disrupt FOXO4–p53 interaction in senescent cells.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Reported adverse effects
- Mouse tolerability cannot establish human safety or an appropriate treatment course.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
The peptide promoted senescent-cell apoptosis and improved selected mouse outcomes; human rejuvenation was not demonstrated.
Selected study only; not a complete clinical review.
Adverseeffects
Mouse tolerability cannot establish human safety or an appropriate treatment course.
Selected study only; not a complete clinical review.
References
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. 2017.
PMID: 28340339
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.